|Bid||0.7400 x 3000|
|Ask||1.1000 x 2900|
|Day's Range||0.7450 - 0.7700|
|52 Week Range||0.5000 - 1.7000|
|Beta (3Y Monthly)||-0.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Every investor in iBio, Inc. (NYSEMKT:IBIO) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller comp...
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for biopharmaceutical production, today announced the appointment of Thomas F. Isett to its Board of Directors, effective immediately. Mr. Isett is an accomplished executive with decades of successful management and corporate development experience in the life sciences, with notable focus upon biologics contract development and manufacturing organizations (CDMOs). Advising, LLC, a management and strategy consulting firm, as well as Commence Bio, Inc., a private, early-stage developer of cellular immunotherapies. As Managing Director of i.e.
NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, announced today that the Second Complaint it filed in iBio’s litigation against the Fraunhofer organization – this time against Fraunhofer Gesellschaft (“FhG”), complaining that FhG had committed fraud against and was responsible for contractual breaches against iBio – was dismissed by the Delaware Chancery Court as untimely filed. The original Complaint filed against Fraunhofer USA, Inc. (“FUSA”) on March 16, 2015, complained of breaches of contracts and misappropriation of iBio trade secrets and other intellectual property causing damages to iBio in excess of $100 million. The Chancery Court, sua sponte, initiated a partial Summary Judgment proceeding and determined that iBio exclusively owns all the technology FUSA developed or otherwise owned anytime before the end of 2014, and was required to transfer all such technology to iBio, but refused to do so. Proceedings under the original Complaint are continuing and are expected to lead to a trial date within the next 12-18 months. The dismissal of the Second Complaint against FhG has no effect on the action against FUSA.
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of Health. “I am honored to have this opportunity to highlight the significant product flexibility, time- and cost-savings provided by iBio’s plant-based technology platform and CDMO offering to my fellow researchers and industry participants and, in so doing, help support the development of new business relationships and commercial collaborations for iBio in Brazil and internationally,” said Dr. Salgueiro.
On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).
I am going to take a deep dive into iBio Inc’s (AMEX:IBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a companyRead More...